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Despite the fact that the local immunological microenvironment shapes the prognosis of colo-
rectal cancer, immunotherapy has shown no benefit for the vast majority of colorectal cancer 
patients. A better understanding of the complex immunological interplay within the microenvi-
ronment is required. In this study, we utilized wet lab migration experiments and quantitative 
histological data of human colorectal cancer tissue samples (n=20) including tumor cells, lym-
phocytes, stroma and necrosis to generate a multi-agent spatial model. The resulting data accu-
rately reflected a wide range of situations of successful and failed immune surveillance. Valida-
tion of simulated tissue outcomes on an independent set of human colorectal cancer specimens 
(n=37) revealed the model recapitulated the spatial layout typically found in human tumors. 
Stroma slowed down tumor growth in a lymphocyte-deprived environment but promoted im-
mune escape in a lymphocyte-enriched environment. A subgroup of tumors with less stroma 
and high numbers of immune cells showed high rates of tumor control. These findings were 
validated using data from colorectal cancer patients (n=261). Low-density stroma and high lym-
phocyte levels showed increased overall survival (hazard ratio 0.322, p=0.0219) as compared 
with high stroma and low lymphocyte levels. To guide immunotherapy in colorectal cancer, 
simulation of immunotherapy in pre-established tumors showed that a complex landscape with 
optimal stroma permeabilization and immune cell activation is able to markedly increase thera-
py response in silico. These results can help guide the rational design of complex therapeutic 
interventions which target the colorectal cancer microenvironment.  
Major Findings (nontechnical description): We present a computer-based model of lymphocyte 
– tumor – stroma interactions. This model reproduces key aspects of human colorectal cancer 
tissue, predicts survival in an independent patient cohort and proposes a new strategy for suc-
cessful immunotherapy in colorectal cancer. 
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Quick Guide to Equations and Assumptions 
Our model is based on a minimal set of assumptions that are backed by our own data or previ-
ously published data. Two types of agents are modeled: tumor cell agents and immune cell 
agents. Immune cells in our model represent T-lymphocytes, whose main fraction are cytotoxic 
lymphocytes. All assumptions for the model are made explicit in Table 1 and all model parame-
ters are listed in Suppl. Table S1. Each agent occupies exactly one position on a two-
dimensional rectangular grid with dimensions N x M and Moore neighborhood (each grid cell 
has eight neighbors). Only one agent can occupy a grid cell. Unlike in other agent-based models, 
all agents occupy the same grid and thus compete for space. This is thought to reflect the na-
ture of colorectal cancer tissue which typically consists of densely packed cells. For simplicity, 
we refer to tumor cell agents as “tumor cells” and to immune cell agents as “immune cells”. 
Upon initialization, one tumor cell is placed in the middle of the domain. Immune cells random-
ly appear each round (constant rate of influx). Then, successively, tumor cells and immune cells 
can act as shown in Figure 1A. Typically, 500 to 5000 model iterations (rounds) are performed 
after which complex spatial patterns can be observed (Figure 1B). In each iteration, each tumor 
cell randomly performs an action, with the following probabilities: Tupdeath for dying, Tupmig 
for migrating to a randomly picked free adjacent position, Tupprol for proliferating. All remain-
ing cells will idle. If a tumor stem cell (stemness true) proliferates, it will generate an identical 
descendant with probability Tups. Otherwise, it will generate a descendant with no stemness. 
After tumor cells have acted, immune cells will act. With probabilities Impdeath, Impmig and 
Impprol they will die, migrate or proliferate. Immune cells do not have a stemness property. 
Sustained immune cell activation can give rise to stroma (fibrosis) through a desmoplastic reac-
tion. Tumor cells and immune cells can be present in fibrotic areas. However, by default, they 
cannot move here (no permeability). The permeability of fibrotic (stromal) areas can be adjust-
ed between 0 and 1 through the parameter stromaPerm. Tumor cells may die and seed necrosis 
with probability probSeedNecr. Necrosis is more likely to occur in the tumor center as its occur-
rence linearly scales with the distance from the smoothed tumor edge. From here on, we use 
the term “stroma” to refer to the tissue generated by fibrosis through exhausted immune cells.  
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Although in reality, stroma might also arise through inflammation-independent mechanisms, 
we restrict our model on stroma induced by ongoing inflammation. To rule out early spontane-
ous tumor death, we required the tumor to be alive at least 50 iterations (or longer, if declared 
otherwise – up to four attempts per experimental run). The time scale of all events is scaled or 
adjusted through intermediary steps in such a way that one main iteration represents 12 hours. 
The resulting agent-based model shows emergent behavior and yields spatial patterns closely 
resembling those in histological samples of human colorectal cancer. 
Introduction 
In recent years, tumor immunotherapy has become available to treat malignant tumors with 
several drugs already approved for solid tumors. Their main mode of action is the activation of 
the adaptive immune system via checkpoint inhibition (1). Other widely used therapeutic strat-
egies aim at increasing the number and the reactivity of effector cells by adoptive cell transfer 
or vaccination (2,3). Additionally, many more drugs are currently investigated in clinical trials, 
especially combination therapies aiming at the stromal compartment (4,5). These approaches 
act on the complex interactions in the tumor microenvironment, as we could show recently in 
macrophage-targeted immunotherapies (6).  
Still, for most patients with solid tumors, no effective immunotherapy strategy is available. Es-
pecially for microsatellite-stable colorectal cancer, the most common form of this disease, im-
munotherapy has been largely ineffective. With a five-year survival of just 11% in metastatic 
diseases (7) and a huge disease burden (8), the therapeutic need is high. In this setting, the de-
velopment of more complex interventions into the immune landscape requires detailed 
knowledge of the interactions of relevant players and their response to interventions. Although 
our understanding of these processes has advanced considerably in the last years, there is still 
no comprehensive systems perspective of all relevant interactions. To understand a complex 
system, it is not sufficient to have a detailed characterization of all its components. Instead, a 
complex system can show emergent behavior that does not arise from a specific component 
but from the interaction of different components.  
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Agent-based models are a powerful method to investigate the interactions in complex systems 
(9). An agent is the smallest unit in this model and can show different types of stochastic behav-
ior, including interaction with other agents. Although these models simplify many aspects of 
reality, they have been shown to be extremely useful in a wide number of circumstances (10-
12). In cancer research, these models are emerging as valuable tools to study emergent behav-
ior in complex ecosystems (13), especially in stem-cell models of tumor growth (14,15) and are 
used to study the mutational landscape of solid tumors (16,17). Furthermore, they are increas-
ingly used to optimize therapies, for example radiation therapy of solid tumors (18). Also, some 
models of immune-cell interactions with (19-24) or without tumor cells (25) have been pro-
posed. Although these studies gave important insight into parts of the tumor-immune interac-
tion, they did not accurately reproduce the diverse spatial patterns in human tumors and did 
not investigate therapeutic strategies.  
In the present study, we generated a multi-agent-based model from quantitative histological 
and other wet lab data, based on the concept of immune surveillance (26). We focused on pa-
rameters that could be morphologically measured and created a simplified yet powerful model 
of cellular interactions that shows emergent behavior. This agent-based model incorporates 
stochastic interactions between tumor cells, immune cells and stroma and faithfully represents 
diverse spatial pattern observed in histological samples of human colorectal cancer tissue. Fur-
thermore, the derived clinical predictions could be validated in an independent colorectal can-
cer cohort. This model was then used to systematically test the effect of different therapeutic 
interventions on this system and to create specific recommendations for effective immuno-
therapies. 
Materials and Methods 
Ethics statement and tissue samples 
All experiments were conducted in accordance with the Declaration of Helsinki, the Interna-
tional Ethical Guidelines for Biomedical Research Involving Human Subjects (CIOMS), the Bel-
mont Report and the U.S. Common Rule. N=20 human tissue samples of colorectal adenocarci-
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noma were used as a calibration cohort. These samples were retrieved from the pathology ar-
chive at UMM (University Medical Center Mannheim, Heidelberg University, Mannheim, Ger-
many) after approval by the institutional ethics board (Ethics Board II at University Medical Cen-
ter Mannheim, decision number 2017-806R-MA, granted to AM and waiving the need for in-
formed consent for this retrospective and fully anonymized analysis of archival samples; Suppl. 
Table S2).  
Another set of 37 colorectal adenocarcinoma samples was used as a morphological validation 
cohort, composed as follows: N=22 tissue samples were provided by the tissue bank of the Na-
tional Center for Tumor diseases (NCT, Heidelberg, Germany) in accordance with the regula-
tions of the tissue bank and the approval of the ethics committee of Heidelberg University (tis-
sue bank decision number 2152, granted to NH and JNK; informed consent was obtained from 
all patients as part of the NCT tissue bank protocol; Suppl. Table S3). N=15 additional samples 
was used as described before (Suppl. Table S3) (27). As the model was designed to be valid for 
all types of colorectal cancer tissues, we included primary tumor samples and colorectal cancer 
liver metastases in all cohorts (Suppl. Table S2 and S3). 
Histological assessment 
We performed histological staining for Ki67 (Dako M7240 antibody, 1:100), active Caspase 3 
(Abcam ab2302 antibody, 1:50) and CD3 (Leica Novocastra NCL-L-PS1 antibody, 1:50) on a Leica 
Bond automatic staining device using a hematoxylin-diaminobenzidine (DAB) staining protocol 
as described previously (6,28). Stained whole slide tissue sections were digitized as described 
previously (6,28). On histological sections, we manually identified areas homogenously occu-
pied by tumor cells or immune cells (in the tumor or around the tumor). The fraction of Ki67-
positive cells (active Caspase 3 positive cells, respectively) was quantified in these regions of 
interest (ROI) per slide using a digital pathology approach analogous to our previously pub-
lished approaches (29,30). Definiens Tissue Studio (Definiens AG, Munich, Germany) was used 
for semi-automatic tissue segmentation and automatic cell segmentation. The fraction of posi-
tive cells was calculated as the number of positively (diaminobenzidine-positive) stained cells 
divided by the number of all cells in the respective ROI. On average, each ROI contained approx-
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imately 3000 cells. Intensity thresholds for cell detection and classification were set manually 
and were identical for all images. The quality of cell segmentation was checked manually for 
each image and was found to be sufficient. We assumed that the median Ki67-positive fraction 
and the median active Caspase 3-positive fraction approximated the probability of a given cell 
type to proliferate or die at one time point. All raw measurements are listed in the Suppl. Data.  
Horizontal migration experiments on lymphocytes in vitro 
For the horizontal migration experiments, Matrigel (undiluted, BD, Germany) was evenly plated 
at the sides of a 24-well chamber in two half-moon shapes (cat eye configuration) and the re-
maining third in between was filled with either pure collagen or Matrigel with CXCL9 (10 ng/ml) 
and CXCL10 (10 ng/ml). After gelling overnight in a humid chamber at 37° C, 5% CO2, the well 
was filled with a thin layer of T cell culture media and healthy donor T lymphocytes (CD3/CD28 
activated and in an independent experiment non-activated) were placed on the right half-moon 
shaped third. After migration for 48 h at 37 °C the resulting distribution in the well was docu-
mented and distances were documented and used for the multi-agent model system. 
Estimation of key parameters 
Initially, our model had 22 parameters, as shown in Suppl. Table S1. These parameters were 
based on a clear set of assumptions. Key assumptions based on previous studies are related the 
tendency of immune cells to migrate towards tumor cells (31-33), lymphocyte exhaustion 
(23,34), desmoplastic reaction (35,36) and stromal permeability (37). All assumptions are listed 
in Table 1. Some of the model parameters had been estimated in previous studies. Specifically, 
this applies to the maximum proliferation capacity of non-stem cells (tumor cells and immune 
cells alike), which we set to 10 analogous to (14). Also, it was previously shown that the maxi-
mum number of kills a lymphocyte can deliver can be validly estimated as five (23). Of the re-
maining parameters, five were measured histologically: Tumor cell proliferation and apoptosis, 
immune cell proliferation and apoptosis and distance to necrosis (Suppl. Figure S1A-F). Thus, 12 
free parameters remained and were set to biologically plausible values (Suppl. Table S1). 
Of 20 tissue samples, 12 contained necrosis and the distance to necrosis from the outer tumor 
margin was measured at three locations, giving 36 distance values. Mean distance was 1.01 
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mm, standard deviation was 0.62 mm so that 90% of all necrotic areas occurred within approx-
imately 2 mm (1.64 sigma, rounded). In the model, the occurrence of necrosis was determined 
by probSeedNecr and it was more likely to be located at the tumor core, with the probability 
linearly increasing from 0 to 2 mm from the outer tumor margin.  
Regarding the scale of the model, we measured cell density of tumor cells in N=20 histological 
samples. We found that tumor cells and immune cells occupy an area of 222.8 µm² (median 
value). Although tumor cells are larger than lymphocytes, the uniform grid required that one 
grid cell should accommodate one cell. This assumption yielded a rectangular grid cells size of 
14.9 µm. Thus, the length of 67 grid cells correspond to one mm. 
Time discretization 
The events in our model (cell proliferation, migration, death) do necessarily occur with the 
same rate at each iteration. To account for these temporal differences, we introduced interme-
diary steps. We assumed that the median Ki67-positive fraction fk is equal to the probability of 
cell division pk in one iteration. Median tumor cell proliferation fraction (as measured in N=20 
tissue samples) was approximately 0.5 (Suppl. Figure S1A) and a full cell cycle typically takes 
approximately 24 hours. Therefore, we set one full iteration of the model as 12 hours. To find 
out the probability of cell death in each iteration, we measured the fraction fc of tumor cells 
and immune cells positively stained for active caspase 3. The process of apoptosis induction to 
completion takes approximately three hours (38), just a quarter of the time step in our model. 
Therefore, the probability of cell death pc in each iteration was scaled appropriately. Regarding 
immune cell movement, we assumed that tumor-infiltrating lymphocytes (immune cell agents) 
migrate with an average speed of approximately 2 µm / min (2880 µm / 24h) (32). These data 
were also qualitatively validated by our in vitro experiments (data not shown). In our model, 
this corresponds to 97 grid cells / 12h (97 grid cells / iteration). Therefore, we introduced in-
termediary steps and allowed immune cells to move up to 97 times per iteration. Lastly, we 
scale the tumor cell killing events: It has been shown that tumor cell killing by cytotoxic T-
lymphocytes is initiated within minutes (39) but takes approximately six hours to complete in 
vitro (40) and in vivo (31). Accordingly, we required that a killing event keeps a lymphocyte en-
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gaged for six hours and only after this period the lymphocyte can kill again (if it is not exhaust-
ed). It has been shown that tumor cell killing might require several hits by lymphocytes (40). 
This was not explicitly modeled in our system. Instead, we assumed that the killing probability 
parameter IMpkill already included multiple hits.  
Outcome assessment 
In our simulation runs, we let the tumors grow for a fixed number of iterations (nSteps) before 
performing changes of the parameters. After an additional number of steps addSteps, tumor 
cell number was compared to the baseline. We assessed the outcome analogously to the RE-
CIST criteria (41) based on the number of tumor cells at T= nSteps+addSteps as compared with 
T= nSteps. Complete remission (CR) was equivalent to the eradication of all tumor cell, partial 
remission (PR) was a reduction in tumor cell number by at least 30%, progressive disease (PD) 
was an increase of tumor cell number by at least 20% and stable disease (SD) described all oth-
er outcomes.  
Computational implementation 
All simulations were implemented in MATLAB® (Mathworks, Natick, MA, USA) R2017a. Parts of 
the code were run in parallel with MATLAB’s Parallel Processing Toolbox. All experiments were 
run on a standard workstation (Intel i7 Processor, 8 cores, 32 GB RAM, Microsoft Windows 
10.1). Typically, computing speed was several hundred simulations per hour. We release all 
source codes for the agent-based model under an open-source license 
(http://dx.doi.org/10.5281/zenodo.853342). 
Clinical data (TCGA) 
To validate the predictions of the model, a clinical validation cohort of N=261 colorectal adeno-
carcinoma (COAD) patients from the NIH (National Institutes of Health) The Cancer Genome 
Atlas (TCGA) collective was used (42). The data was downloaded via the TCGA Data Portal as 
described before (43). All TCGA samples that were included in the analysis are listed in Suppl. 
Table S4. 
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To assess the association between overall survival, stroma, lymphocytes and their interaction, 
we performed a survival analysis of the TCGA collective. Cox proportional hazard models were 
fitted, including overall survival as a dependent variable, and lymphocytes (high/low), stroma 
(high/low), and the interaction of lymphocytes and stroma as fixed factors. Lymphocyte infiltra-
tion and stroma content of tumor tissue were part of the data tables available at the TCGA data 
portal. These variables had been manually measured by pathologists as part of the original 
TCGA data curation. Patients were split into low and high at the median. Due to its role as a 
potential confounder, TNM status was also included into the model as a fixed factor. Hazard 
ratios for effect estimates with corresponding 95% confidence intervals, and p-values for haz-
ard ratios and the interaction term were computed. P-values smaller than 0.05 were regarded 
as statistically significant. The analysis was carried out using SAS v9.4 (SAS Institute, Carey, NC, 
USA). Furthermore, a Kaplan-Meier plot displaying the product-limit survival estimates along-
side the number of subjects at risk for each of the four strata was created.  
Results 
The model recapitulates major immune phenotypes of solid tumors 
We propose a new agent-based model of tumor-immune cell interactions that is based on a 
minimal set of assumptions (Table 1) and parameters (Suppl. Table S1). In this model, we ob-
served emergent behavior on different scales, particularly with regard to tumor tissue mor-
phology. Generally, four types of immunological phenotypes can be distinguished histologically: 
hot tumors, cold tumors, immune excluded tumors (with an immune cell rim around the tumor) 
and tumors that have been (almost) completely eradicated by immune cells (44). Our agent-
based model was able to reproduce all these spatial patterns as shown in Figure 2A-D. We con-
cluded that the model is in principle able to model all relevant types of immune surveillance in 
solid tumors.  
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The model faithfully represents spatial patterns compared with histological data 
To compare our model with histological spatial patterns in an objective way CD3-stained colo-
rectal cancer tissue samples were used. This analysis entailed all N=20 tissue samples from the 
calibration cohort (Suppl. Table S2) and N=37 additional samples from an independent valida-
tion cohort from a different institution (Suppl. Table S3). We analyzed spatial features of tu-
mor/stroma distribution and found that the spatial layout of CD3-positive lymphocytes was 
always part of the spectrum of cold tumors (Figure 2A), hot tumors (Figure 2B), immune ex-
cluded tumors (Figure 2C) or eradicated tumors (Figure 2D). Specifically, resulting tumor nod-
ules showed varying degrees of fibrosis and necrosis, mirroring spatial patterns in histological 
samples. This is shown in Suppl. Figure S2 A-C for an immune-excluded non-necrotic tumor, in 
Suppl. Figure S2 D-F for a largely necrotic tumor and in Suppl. Figure S2 G-I for a cold tumor 
with stromal core. We conclude that based on a calibration cohort and a morphological valida-
tion cohort, the model reproduced spatial architecture of tumor cells, stroma and lymphocytes 
sufficiently. 
Stroma deprivation enables tumor eradication in a lymphocyte-enriched environment in silico 
To better elucidate the emergent dynamics, the behavior of tumors under different environ-
mental conditions were investigated. In particular, we investigated immunological dynamics 
(immune surveillance) of a typical tumor with varying tumor-stroma ratio and varying numbers 
of tumor-reactive lymphocytes. To this end, we simulated the growth of 50 tumors for 60 days. 
At this point, tumors had reached a size of close to 5000 cells. Then, the immune cell influx was 
strongly increased (immune boost) and the parameter for stroma induction was varied to gen-
erate tumors with different lymphocyte and stroma contents (Figure 3A). According to these 
variations, four types of host response were investigated: Low and high stroma (Stro) genera-
tion (fibrosis seeding) and low and high immune cell (Lym) number. 
We observed that the groups showed a drastically different behavior: Tumors in the “Stro low, 
Lym low” group showed an unhindered, exponential growth (Figure 3B). In comparison, the 
growth in the “Stro high, Lym low” group was slower, but still steadily rising. As can be seen in 
Figure 3C, both “Lym low” groups presented largely with progressive disease (PD) states at six 
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months (180 days) after baseline. In contrast, a higher number of lymphocytes (Lym high) led to 
a phenotype with restrained tumor growth, as expected. Specifically, in the subgroup “Stro 
high, Lym high”, tumor size was constrained to under 10000 cells (Figure 3B and C). Surprising-
ly, the “Stro low, Lym high” group showed an altogether different behavior: after an initial in-
crease in tumor mass (Figure 3B), inflowing immune cells regained control and completely erad-
icated the tumor in almost all simulation runs (Figure 3C, Suppl. Figure S3).  
Clinical validation of the predicted immunological dynamics demonstrates a combined risk fac-
tor 
In the model, the sub-group of tumors “Stro low, Lym high” by far the most favorable outcome 
of all simulated tumors. Tumor eradication reproducibly occurred only in the “Stro low, Lym 
high” group and not in the “Stro high, Lym high” group. This suggests that a high number of 
lymphocytes can only successfully constrain tumor growth if there is little stroma in the tumor. 
We validated this prediction by analyzing a cohort of N=261 patients from the TCGA database 
based on publicly available records (42,43). For all patients, a manual histopathological quanti-
fication of stroma and lymphocytes was available as well as clinical follow-up data. Patients 
were stratified into high and low stroma content and lymphocyte number at the median. The 
only sub-group with a significant overall survival benefit as compared to the other groups was 
“Stro low, Lym high” in comparison to “Stro high, Lym high” group, as assessed by our Cox pro-
portional hazards model (hazard ratio 0.309 for overall survival 0.322, p=0.0219, confidence 
interval 0.122 to 0.849, Figure 4A), reflected also by Kaplan-Meier curves for all groups (Figure 
4B) . “Stro” and “Lym” alone were no significant predictors of overall survival and neither were 
all other subgroups as shown in Figure 4A. The p-value for the interaction between “Lym” and 
“Stro” was p=0.1192. Taking into account that the interaction test is commonly subject to a 
very small power (45), p=0.1192 for an interaction test, even though not statistically significant, 
can be deemed as an indicator for a quite prominent interaction between “Lym” and “Stro”. 
An optimal combination of immunotherapy and stroma-targeted therapy 
Having confirmed stroma as an important modulating factor in the in silico experimental setup, 
we simulated an immunotherapy together with stroma targeting therapy. A simple yet realistic 
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way of simulating stroma-targeted therapy is to modify the permeability of stroma with regard 
to cell migration (46,47). Therefore, we let tumors grow to a diameter of approximately 2 mm, 
which was typically reached after 120 days (Figure 5A). Then, we simulated an “immune boost”, 
increasing the number of immune cells 2-fold, 4-fold and 8-fold. Also, stroma was permea-
bilized with a factor of 4%, 8% and 16%. In accordance with our previous results, we saw that 
non-permeable stroma inhibited a tumor eradication (Figure 5B).  
In tumors with low stroma permeability and/or low lymphocyte numbers, we observed mostly 
tumor progression, characterized by four typical phenotypes: stroma acting as a physical barrier 
that protects the tumor (Suppl. Figure S4A), rapid tumor outgrowth of immune control (Suppl. 
Figure S4B), tumors breaking through a physical barrier (Suppl. Figure S4C) and excessive im-
mune cell exhaustion (Suppl. Figure S4D).  
Contrariwise, tumors with high stroma permeability and high lymphocyte numbers were suc-
cessfully eradicated in 75% of all simulation runs (Figure 5B). There was a striking duality in the 
effect of stromal permeabilization: In a lymphocyte-deprived environment, permeabilizing 
stroma had an adverse effect and led to increased tumor progression (bottom row in Figure 
5B). With highly permeable stroma, this adverse effect persisted also in 2-fold immune boosting 
and was only superseded by a strong immune boost of 4-fold.  
From these in-silico experiments with clinical validation, we conclude that stroma, arising 
through post-inflammatory fibrosis, has a dual role in solid tumors: under usual conditions, it 
can mitigate tumor growth to a small degree. After a simulated immune boost, stroma provides 
a mechanism for immune escape. Only the permeabilization of stroma in combination with 
immunotherapy can lead to tumor regression in this model. 
Discussion 
Within the concept of tumor immune surveillance, tumor cells and immune cells are engaged in 
an ongoing battle (26). From a conceptional perspective, a tumor disease develops if tumor 
cells temporarily win this fight by means of immune evasion. In line with this, immunotherapy 
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aims at activating the T cells and thereby leading to tumor eradication in some patients. For 
colorectal cancer (microsatellite stable tumors), so far, no immunotherapy has shown efficacy. 
Driven by the clinical need to better understand the processes of immune evasion and activa-
tion, we developed a computer-based model that allowed us to investigate the dynamics gov-
erning tumor-immune cell interaction on a systems level (Figure 1A). This model was generated 
utilizing quantitative histological and other wet lab data as well as data from previous studies 
(Suppl. Table S1).  
The model was fitted to histological data in two ways: First, quantitative histological data from 
Ki67 and active Caspase 3 immunostainings was used to estimate the proportion of actively 
dividing and dying cells as well as the overall cell density. In a second step, N=37 human tumor 
tissue samples were used to show that the naturally occurring spatial patterns could be repro-
duced by our model, even on a large spatial scale (Suppl. Figure S2A-I). 
Using this validated in silico model, a consistent and highly relevant interaction between lym-
phocytes and stroma was discovered: In an immune-deprived environment, stroma restrains 
tumor growth and tumors with little stroma grow faster. In contrast, in an immune-cell en-
riched environment, stroma inhibits tumor cell killing thus, immune-cell rich tumors with low 
amounts of stroma are eradicated while immune-cell rich tumors with high amounts of stroma 
are not (Figure 3). This leads to a bivariate risk-factor model for colorectal cancer that was vali-
dated in two independent validation steps: a morphological validation in n=57 tissue samples 
(Figure 2A-D, Suppl. Figure S2A-I) and a clinical validation in a set of n=261 patients (Figure 4A-
B). 
As a next step, immune cell numbers and stromal permeability were gradually varied (Figure 
5B). Strikingly, a very consistent pattern was apparent: increasing the number of lymphocytes 
could only lead to tumor eradication if stromal permeability was also increased, in a dose-
dependent manner (Figure 6). Stromal permeability increase without lymphocyte-enrichment 
was detrimental and led to faster tumor progression (Figure 6). This has important clinical con-
sequences: increasing stromal permeability might greatly enhance the effectiveness of immu-
notherapy, but can also be dangerous if the tumor microenvironment is lymphocyte-deprived. 
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Currently, several experimental therapies in the clinic aim to target the stroma. Indeed, most 
prominent are approaches with enzymes that aim to enhance the permeability of stroma 
(4,5,48). Our data show that these approaches can be very effective but can also have adverse 
effects need to be considered before clinical development of new substances. Thus, for future 
clinical trials, the balance between stroma-targeting interventions and lymphocyte-targeting 
interventions should be investigated at the pre-clinical stage. In-silico models such as our model 
could be a part of this pre-clinical pipeline. 
The contribution of stroma reaction and inflammation in colorectal cancer has been investigat-
ed before, jointly for both factors (49) or separately (50,51). However, to our knowledge, we 
report for the first time a bivariate interaction effect of both risk factors and provide an expla-
nation for this behavior through in silico experiments. Our findings regarding fibrosis are in line 
with previous observations in biological studies and explain previous observations. Pancreatic 
cancer, for example, typically has pronounced tumor fibrosis. It has been shown that reducing 
fibrosis in this cancer benefits the tumor and reduces survival in a mouse model (52). This be-
havior also arises in our model. Furthermore, in line with our simulations, it has been shown 
that tumors can use the stroma to mitigate the immune response (53). Regarding immunother-
apy, it has been suggested that immune response against a tumor is more efficient if the im-
mune cells also destroy the stroma (48). Our model provides a simple explanation for this be-
havior.  
Like all models, our model is not an exact copy of reality but simplifies some key aspects of real-
world tumors. For example, killing of tumor cells by immune cells is a purely stochastic process 
in our model. Fine-tuning through T cell specificity, tumor immunogenicity and other co-
stimulatory or inhibitory factors are not explicitly modeled but are summarized in the “killing 
probability”. Also, the model does not explicitly include myeloid cells or other regulating factors 
for lymphocyte-mediated cytotoxicity. In the future, myeloid cells – and the crucial regulation 
of lymphocyte activity via macrophages (6) – could be incorporated into more complicated 
models.  
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While these simplifications constrain the implications that can be drawn for certain molecular 
or signaling processes, it allows us to focus on the emergent features of the cellular interaction 
between key players in the tumor microenvironment. Most importantly, our model takes into 
account several quantitative histological observations and is thus partly calibrated with real-
world tumors. Also, our model includes post-inflammatory fibrosis which gives rise to unex-
pected and informative emergent behavior. It therefore guides the possible translational devel-
opments, especially in selecting the ideal combination partners for synergistic clinical effects 
(Figure 6). This provides therefore a roadmap for an iterative enhancement of immunotherapy 
for immunologically “cold” tumors.  
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Figures 
Figure 1: Flowchart of the algorithm and visualization: an agent based model that generates 
realistic tumor nodules. (A) In our agent-based model, tumor cell agents and immune cell 
agents occupy a rectangular grid and can successively act. All cells migrate, divide, idle or die 
with fixed probabilities. Immune cells show a tendency to migrate towards tumor cells and can 
kill them. Immune cells that have killed five times become exhausted and can induce fibrosis. 
Tumor cells conglomerates can become necrotic. This process is repeated 500 – 5000 times. 
Intermediary steps for accurate time scale discretization are not shown. (B) Tumor cells are 
shown in red and shaded according to their remaining proliferative potential. Immune cells are 
shown in blue and shaded according to their remaining kills. By default, fibrosis (stroma) is 
almost completely impermeable to all cells and shown in yellow, while necrosis is permeable to 
immune cells and shown in black. Scale bar: 2 mm.  
Figure 2: The model reproduces major immunological phenotypes of tumors. In general, four 
types of immune phenotypes can be distinguished: hot and cold tumors, immune excluded or 
eradicated tumors (fibrous scar). The agent-based model yields all those four phenotypes, de-
pending only on the variation of two parameters (related to fibrosis generation and tumor cell 
killing). (A) cold tumor, (B) hot tumor, (C) immune excluded phenotype, (D) tumor eradication. 
Scale bars: 2 mm. 
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Figure 3: Stroma slows tumor growth in a lymphocyte-deprived, but mediates immune escape 
in a lymphocyte enriched environment. (A) experimental design, (B) tumor mass over time for 
all four groups, depending on probability of stroma generation (Stro low vs. high) and the mag-
nitude of immune cell influx (Lym low vs. high) (C) outcome three months after baseline (60 
days, dashed line). Response criteria were chosen analogous to the RECIST criteria (41). The 
subgroup “Stro low, Lym high” had a 100% response rate, the majority complete responses (i.e. 
eradication of all tumor cells). Abbreviations: PD = progressive disease, SD = stable disease, PR = 
partial remission, CR = complete remission.  
Figure 4: High lymphocyte number and low stroma define a subgroup with longer survival in 
TCGA colorectal cancer patients. Data from N=261 patients, publicly available through records 
from the TCGA database. (A) Hazard ratios are shown for overall survival together with 95% 
confidence intervals and are adjusted for TNM status. (B) Kaplan-Meier plot for all four strata 
(product-limit survival estimates, number at risk shown below). 
Figure 5: Increased stromal permeability can lead to tumor hyperprogression or eradication, 
depending on the immune cell number. (A) experimental procedure, (B) outcome in compari-
son to baseline by varying degrees of immune boosts and stromal permeability changes. Verti-
cal axis from bottom to top: baseline, then 2-fold, 4-fold and 8-fold immune boost. Horizontal 
axis from left to right: stromal permeability baseline, then increase by 4%, 8% and 16% (100% 
being completely permeable). N=24 technical replicates per group. Stromal permeabilization 
leads to increased tumor progression, but enables tumor eradication if combined with an 8-fold 
immune boost.  
Figure 6: Proposed model of combination effects of immunotherapy and stromal-targeted 
therapy: stromal depletion or permeability increase can lead to different outcomes. Our mod-
el suggests a crucial combination effect of stromal-targeting and immune-enhancing therapy. 
Activation of the adaptive immune response alone can stop tumor growth but cannot eradicate 
tumors. Stromal depletion or permeabilization alone benefits the tumor cells and leads to hy-
perprogression. Only the combination of stromal permeabilization and immune boosting ena-
bles tumor eradication. 
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All cells can migrate, proliferate and die. trivial 
Tumor cells are composed of stem cells and non-stem cells. Stem cells can divide 
symmetrically with a fixed probability.  
(14) 
Stem cells can proliferate indefinitely, all other cells die after a fixed number of 
proliferation cycles.  
(14) 
All cells can spontaneously enter apoptosis. own data 
Tumor cells can spontaneously enter necrosis own data 
Tumor cells that are far from the outer margin have a higher probability of en-
tering necrosis than those cells closer to the margin. 
own data 
Immune cells are generated through a steady influx into the domain and prolif-
eration within the domain. 
(32),  
own data 




Immune cells can kill adjacent tumor cells whenever they are close enough. Kill-
ing, like other events in the model, occurs stochastically with a fixed probability 
and is not regulated by other factors. 
(23) 
Immune cells can kill five times before they become exhausted, which means 
that they cannot kill anymore but can still proliferate. 
(23,34) 
Activated immune cells give rise to stroma through a desmoplastic reaction 
(stroma reaction). For simplicity, this behavior is restricted to immune cells that 
have successfully killed five times in the model. 
(35,36) 
By default, cells cannot migrate through stroma, but stromal permeability can 
be increased optionally. 
(37) 
Table 1: Assumptions for the model and references for each assumption. For each assumption, 
one or more supporting references are listed. “Own data” refers to histological and wet-lab 
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